Who
Jonathan P. Foster
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Moleculin Biotech; Director, Empery Digital; Director, Soliton; Chief Financial Officer, InfuSystems Holdings.
In numbers
- Trades disclosed
- 94
- Buys
- 8
- Sells
- 0
- Bought
- $160K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 13 Mar 2014
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —130,000 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $11K30,485 at $0.3701 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —130,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Bought | —293,333 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code P | —879,999 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code P | —879,999 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Bought | —293,333 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —174 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —174 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $12841 at $3.12 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —174 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —174 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $12841 at $3.12 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —109 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $8931 at $2.88 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —109 at $0.00 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —109 at $0.00 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —109 | filing |
News
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitMBRX · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Jonathan P. Foster; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.